Compare T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Inverse MSTR Daily Target ETF vs Novo Nordisk A/S — how do they compare? T-Rex 2X Inverse MSTR Daily Target ETF trades at $4.35, while Novo Nordisk A/S trades at $45.1 (market cap $198.57B). The key difference: Novo Nordisk A/S pays a 4.03% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| MSTZ | NVO | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $27.92 | $63.98 |
52-Week Low | $3.63 | $35.29 |
Market Cap | — | $198.57B |
Enterprise Value | — | $213.37B |
Dividend Yield | — | 4.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTZ trades at $4.04, up 8.46% in the last 24 hours, but technical indicators signal a bearish trend with moving averages and ADX strongly bearish. The stock lacks disclosed financial ratios, suggesting limited fundamental data availability. Recent news highlights ETFs betting against related stocks, indicating negative sentiment in its sector.
The outlook is cautious due to bearish technicals and sparse fundamentals. Risks include market volatility and competitive pressures, with no clear catalysts for upside. Investors should seek updated financial filings for a clearer assessment.
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
